Inaugural KCSH Conference: Shaping the Future of Smart Health

Inaugural KCSH Conference:

Shaping the Future of Smart Health

May 14 - 15. 2025

KAUST Library

ABOUT THE EVENT

The KAUST Center of Excellence for Smart Health (KCSH) is delighted to announce the Inaugural KCSH Conference: Shaping the Future of Smart Health, taking place on May 14 and 15, 2025, at the KAUST Library. This event will celebrate the achievements of the KCSH by showcasing the latest research in health and wellness of KCSH faculty members and providing a platform for high-level discussions on the future of health innovation.

This event will bring together faculty, researchers, strategic national stakeholders, regional healthcare sector entities, and key international stakeholders and experts to explore cutting-edge advancements in smart health and their impact on the future of healthcare in the Kingdom and beyond.

CALL FOR E-POSTERS:

Call for poster presentation is closed

AGENDA

08:30 - 09:00

Welcome Refreshments and Registration

09:00 - 09:20

Event Opening and Welcoming Remarks

Session Chair: Prof. Imed Gallouzi, Chair of KAUST Center of Excellence for Smart Health (KCSH)

09:05 - 09:10

Prof. Sir Edward Byrne AC, President of KAUST

09:10 - 09:15

Ibn Sina Distinguished Prof. Pierre Magistretti, Vice President for Research, KAUST

09:15 - 09:20

Prof. Imed Gallouzi, KCSH Chair, KAUST

09:20 - 10:20

Session 1: Healthy Brain; Healthy Lifespan

Session Chair: Prof. Imed Gallouzi, Chair of KAUST Center of Excellence for Smart Health (KCSH)

09:20 - 09:50

Mitochondrial Cytopathies to Ageing – An Interesting Journey

Prof. Sir Edward Byrne AC, President of KAUST

09:50 - 10:20

Brain Health and Aging: A Metabolic Perspective

Ibn Sina Distinguished Prof. Pierre Magistretti, Vice President for Research, KAUST

10:20 - 11:00

Coffee Break and Networking Session

Scientific posters and displays

11:00 - 13:00

The National Anthem of the Kingdom of Saudi Arabia

Session 2: Strategic National Partnerships

Session Moderator: Prof. Imed Gallouzi, KCSH Chair, KAUST

11:00 - 11:30

Address from His Royal Highness, Prince Sultan bin Salman bin Abdulaziz Al Saud

Special Advisor to the Custodian of the Two Holy Mosques,

Chairman of the Board of Trustees of the Non-profit King Salman Foundation, and Chairman of the Board of Trustees of the King Salman Center for Disability Research (KSCDR)

- Inauguration of KSCDR Sponsored Research Project, led by Prof. Robert Hoehndorf, Assoc. Prof. of Computer Science, KAUST

11:30 - 11:45

Keynote Talk from Mr. Sami AlSager

Vice President for Operations, SFDA

SFDA-KAUST Memorandum of Understanding Ceremony

11:45 - 12:00

Dr. Abdullah bin Zarah

CEO of Prince Sultan bin Abdulaziz Humanitarian City (SBAHC)

SBAHC-KAUST Memorandum of Understanding Ceremony

12:00 - 12:10

Eng. Nizar Al Hariri, Senior Advisor to the Minister of Industry and Mineral Resources

12:10 - 12:20

Dr. Mahmoud AlYamany, Head of NEOM Health and Wellbeing, NEOM

12:20 - 12:30

Dr. Petros Kotsidis, Chief Digital Officer, King Faisal Specialist Hospital & Research Centre (KFSH&RC)

12:30 - 12:40

Dr. Naila Pioger, Sr. Medical and Clinical Development Director, Novo Nordisk Saudi Arabia

12:40 - 12:50

Dr. Essam A. Tawfik, GM, Advanced Diagnostics & Therapeutics Institute, King Abdullah City for Science and Technology (KACST)

13:00 - 14:30

Lunch

Group photo

Scientific posters and displays

14:30 - 15:50

Session 3: Innovation to Impact in Smart Health

Session Chair: Prof. Arnab Pain, Prof. of Bioscience, KCSH Executive Committee, KAUST

14:30 - 14:40

Novel Therapeutics to Prevent Disease Induced Muscle Loss

Prof. Imed Gallouzi, Prof. of Bioscience, KCSH Chair, KAUST

Abstract

Abstract

Novel Therapeutic to Prevent Disease Induced Muscle loss

Cachexia, a debilitating muscle-wasting syndrome associated with cancer, chronic diseases, and aging, remains without effective treatment and contributes to poor patient outcomes and high mortality. Over the past two decades, our lab has investigated the post-transcriptional regulation of skeletal muscle formation, identifying the RNA-binding protein HuR as a key regulator of myogenesis. Unexpectedly, we found that HuR also promotes cachectic muscle loss, in part by stabilizing mRNAs encoding pro-wasting factors such as inducible nitric oxide synthase (iNOS). Given the role of iNOS in suppressing promyogenic gene expression and its upregulation in cachectic muscle, we hypothesized that it could serve as a therapeutic target. Our studies using both genetic and pharmacological models confirmed that iNOS inhibition protects against cachexia-induced muscle loss. Notably, we identified two novel compounds that suppress iNOS more effectively than existing inhibitors, restore protein synthesis, and preserve muscle fiber integrity. These findings not only establish iNOS as a viable and druggable target for cachexia, but also open new avenues for addressing muscle degeneration in aging and chronic disease.

14:40 - 14:50

Large Language Models in Skin Disease Diagnostics and Cosmetology

Prof. Xin Gao, Prof. of Computer Science, KCSH co-Chair, KAUST

Abstract

Abstract

Large Language Models in Skin Disease Diagnostics and Cosmetology

Large language models (LLMs) have shown remarkable success in various applications, such as content generation, translation, and code development. Yet its applications in biomedical and health domains are to be explored. In this talk, I will introduce SkinGPT-4, the first multi-modality LLM for skin disease diagnostics. I will further introduce BeautyX, an LLM for cosmetology.

14:50 - 15:00

Development and commercialization of PCR diagnostic kits for human pathogens

Prof. Samir Hamdan, Prof. of Bioscience, Associate VP and COO for Research, KAUST

Abstract

Abstract

Development and commercialization of PCR diagnostic kits for human pathogens

Here, I will present Thuwal BioLabs (TBio), a biotechnology company registered in Saudi Arabia, specialises in the development of state-of-the-art in vitro diagnostic kits. The company addresses critical healthcare needs both domestically and internationally, focusing on respiratory diseases, Flaviviridae viruses’ diseases and mandatory testing for employment and marriage visas within the Kingdom of Saudi Arabia. TBio has established strong partnerships with several leading healthcare institutions in Saudi Arabia, including the Food and Drug Authority, Public Health Authority, King Fahad Specialist Research Hospital, NoorDx Diagnostics, and Jeddah Regional Labs. These collaborations play a critical role in the clinical validation of TBio’s products, providing access to valuable patient samples and real-world testing environments. Tbio’s vision is to establish a strong base in Saudi Arabia, ensuring the availability of high-quality products for local markets while also building a global footprint that enables TBio to compete on international levels. The company’s strong commitment to regulatory standards, combined with robust partnerships and access to cutting-edge facilities, provides a solid foundation for sustainable, long-term success. TBio is strategically positioned to deliver high-performance diagnostic solutions that meet the growing needs of both local and global markets, ensuring the highest standards of quality and reliability.

15:00 - 15:10

Leveraging the power of Mendelian Genetics for Target Identification and Drug Development

Prof. Bruno Reversade, Prof. of Bioscience, KAUST

Abstract

Abstract

Over the last 15 years, a revolution in the speed, cost and accessibility of high volume sequencing has introduced a paradigm shift in the field of personalized medicine. While GWAS/EWAS/PheWAS have helped elucidating the genomic basis of complex diseases, their direct contribution to mechanism-based intervention strategies remains somewhat limited. In contrast, Mendelian phenotypes – Nature's own experiment – remains the primary tool for assigning causality and function to our genes. Through a selection of more or less compelling examples, I will illustrate how the investigation of unique heritable traits can be pivotal in identifying and validating novel therapeutic targets and advancing translational drug development programs.

15:10 - 15:20

Next-Generation Minimally-invasive Biosensing and Drug Delivery Platforms enabling Accessible Precision Healthcare

Prof. Dana Alsulaiman, Asst. Prof. of Material Science and Engineering, KAUST

Abstract

Abstract

Next-Generation Minimally-invasive Biosensing and Drug Delivery Platforms enabling Accessible Precision Healthcare

Assistant Professor Dana Alsulaiman

Division of Physical Science and Engineering, King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia

*E-mail: dana.alsulaiman@kaust.edu.sa

The future of precision and personalized healthcare hinges on key enabling technologies that deliver timely and accurate healthcare insights and medical interventions. My Lab (the BioMAD lab) focuses on engineering advanced material-based platforms that address urgent clinical needs through next-generation diagnostics and therapeutics. In this seminar, I will showcase three cutting-edge technologies that drive precision health. First, I will present our portable, 2D materials-enabled electrochemical biosensors, designed for ultrasensitive and rapid detection of key biomarkers—including microRNA for early cancer detection, vitamin D for nutritional monitoring, and SARS-CoV-2 for infectious disease diagnostics. These low-cost, robust platforms are amenable for decentralized and resource-limited settings, advancing the accessibility of healthcare solutions. Next, I will introduce ProT-patch, a smart microneedle patch capable of efficiently delivering large proteins into targeted skin layers. This miniaturized, painless drug delivery platform overcomes major challenges in transdermal delivery, unlocking new possibilities in therapeutics, cosmetics, and vaccine administration. Finally, I will highlight our research in single-molecule biosensing which relies upon DNA-based data encoding systems and nanopore readouts for high-throughput detection of rare disease biomarkers—even under extreme conditions encountered in space exploration – already gaining the interest of NASA researchers. Ultimately, at the interface between material science and bioengineering, the BioMAD Lab is uniquely positioned to advance smart health solutions addressing critical challenges in Saudi Arabia and beyond— through early detection of age-associated diseases and transformative drug delivery tools.

15:20 - 15:30

From Sensors to Insights: Transforming Healthcare, and Beyond

Prof. Khaled Salama, Prof. of Electrical and Computer Engineering, KAUST

Abstract

Abstract

From Sensors to Insights: Transforming Healthcare, and Beyond

This talk explores the impact of wearable sensor technologies in healthcare highlighting how AI integration at the sensor level enhances their functionality. Wearable sensors enable real-time monitoring for patient care, pollution tracking, and non-invasive marine studies, with advancements in miniaturization and energy efficiency expanding their applications.

A key focus is extreme edge intelligence, which processes data directly on sensors to improve efficiency, privacy, and responsiveness. However, this comes with challenges, such as limited computational power. Through multiple case studies, the seminar will showcase AI-driven innovations: bio-inspired gas sensors, enhanced magnetic sensors for deep learning, and AI-powered wearable sensors for real-time health monitoring.

By merging AI with wearable sensors, this seminar highlights a shift towards smarter, more autonomous sensing technologies, unlocking new possibilities across multiple fields.

15:30 - 15:40

From Crisis to Preparedness: Advancing Health Security with a Rapid-Response Vaccine Platform

Prof. Magnus Rueping, Prof. of Chemical Science, KAUST

Abstract

Abstract

From Crisis to Preparedness: Advancing Health Security with a Rapid-Response Vaccine Platform

The outbreak of the SARS-CoV-2 pandemic catalyzed a wave of groundbreaking vaccine development, culminating in an unprecedented global vaccination effort. Since the first approval of a COVID-19 vaccine in December 2020, over 13 billion doses have been administered worldwide. However, SARS-CoV-2 has demonstrated a troubling combination of high transmissibility, elevated mortality, rapid adaptation, and immune evasion. These features have led to the continuous emergence of new variants, progressively reducing the effectiveness of available vaccines and prompting repeated reinfection waves. Consequently, populations have required booster doses to maintain adequate protection. Although new generations of mRNA-based COVID-19 vaccines are advancing through clinical trials and regulatory processes, they still face significant limitations. Among these are persistent adverse immune reactions. To address these challenges and strengthen pandemic preparedness, we have developed KV-0620, a broad-spectrum booster vaccine designed not only to tackle the limitations of current vaccines but also to function as a flexible and rapid-response platform in future pandemics. KV-0620 offers robust cross-variant protection, improved tolerability, and scalable deployment potential; key features that align with long-term strategies for local and global health security.

15:40 - 15:50

Surveillance of Dengue in the KSA and Oman

Prof. Arnab Pain, Prof. of Bioscience, KAUST

Abstract

Abstract

Dengue continues to pose substantial public health challenges globally. In recent years, Dengue has become a significant public health concern in KSA and also in Oman. Supported by the KAUST Centre of Excellence for Smart Health (KCSH) and in active collaboration with the Saudi Ministry of Health (MoH) and Sultan Qaboos University in Muscat, we are undertaking a large-scale genomics-driven Dengue virus surveillance program in the KSA and Oman. These studies provide the first set of high-quality, full-length DENV genomes from the Middle East and North Africa (MENA) region. Our findings offer critical insights into the molecular epidemiology and evolutionary dynamics of circulating DENV in KSA and Oman, and underscore the value of genomic surveillance for informing public health responses and improving outbreak preparedness across the region.

15:50 - 16:10

Coffee Break and Networking Session

16:10 - 17:00

Session 4: Panel Discussion: Autism: Igniting Child Development with AI and Sensors

Session Moderator: Prof. Ahmed Eltawil, Prof. of Electrical and Computer Engineering, KCSH

Executive Committee, Associate Dean for Research, CEMSE, KAUST

Panelists:

Dr. Mahmoud AlYamany, Head of NEOM Health and Wellbeing, NEOM

Prof. Leena Ibrahim, Asst. Prof. of Bioscience, KAUST

Dr. Paul O’Callaghan, Manager, Family and Child Support Center (FCSC), KAUST

17:00 - 17:10

Closing Remarks for Day 1

Prof. Imed Gallouzi, KCSH Chair, KAUST

08:30 - 09:00

Welcome Refreshments and Registration

09:00 - 10:50

Day 2 Opening and Welcoming Remarks

Session 5: Innovation to Impact in Smart Health

Session Chair: Prof. Jasmeen Merzaban, Assoc. Prof. of Bioscience, KCSH Executive Committee, KAUST

09:10 - 09:30

Fundamental science meets academic medicine: a rewarding challenge

Prof. Matthias Hentze, Director, European Molecular Biology Laboratory (EMBL)

Abstract

Abstract

KAUST represents a center of excellence in fundamental science, including the life and health sciences. Its scientific output includes many touch points with clinical medicine, and taking optimal advantage of these will multiply opportunities and amplify KAUST’s societal impact and deliveries. I co-founded the Molecular Medicine Partnership Unit (MMPU) between the European Molecular Biology Laboratory (EMBL) and the Medical

Faculty of Heidelberg University in 2002, and served as its Co-Director for over 20 years. I will describe the MMPU as a “case study” of establishing mutually beneficial, organically growing and intensifying links between two ‘worlds’ that can give each other much, but that have to overcome profound challenges. I will highlight aspects that have proven to be MMPU drivers of success.

09:30 - 09:40

Quantum Medicine is the future Precision Medicine for Chronic Diseases

Dr. Khalid Al-Rubeaan, Director, Research & Scientific Center, Prince Sultan Bin Abdulaziz Humanitarian City (SBAHC)

Abstract

Abstract

Quantum Medicine is the future Precision Medicine for Chronic Diseases

The role of chemistry and physiology in medicine has been recognized since Hippocrates time around 420 BC. Over the next 2500 years other science fields namely anatomy, biology, botany, and organic chemistry had their role in the development of medicine. The development of recent medicine was brought-up by advance technology of pathology, molecular biology, microbiology, pharmacology and physics. As the field of medicine grows, new scientific field development holds great promise for improving clinical research and will improve both disease diagnosis and management. Physics did not take its proper share in the development of medicine except in radiology and some medical technology which deprived humanity from many physics’ applications. Quantum medicine is a field that is expected to empower medicine in its different sections. For disease diagnosis incorporating quantum mechanics will allow for efficient diagnosis before symptoms even arise. Quantum Computing has the potential to revolutionize genomic analysis by enabling faster and more accurate processing of large amount of data genome assembly and variant detection. Quantum theory can even give explanations for DNA changes and even telomere reduction in patients with cancer. Quantum dots produce nanoscale semiconductor particles possess unique optical and electronic properties, making them valuable tools for imaging biological processes, diagnostics, and therapy, as an exciting application of quantum physics in medicine. Theory-based mathematical structures for neuronal transmission throughout the brain on a quantum scale helps to understand neurological diseases.

09:40 - 09:50

FedMedICL: Towards Holistic Evaluation of Distribution Shifts in Federated Medical Imaging

Prof. Bernard Ghanem, Chair of Center of Excellence for Generative AI, KAUST

09:50 - 10:00

Center of Excellence on Renewable Energy and Storage Technologies at KAUST

Prof. Husam AlShareef, Chair of the CoE for Renewable Energy and Storage Technologies, KAUST

10:00 - 10:10

Title TBC

Prof. Salim Al-Babili, Prof. of Plant Science, Associate Dean, BESE, KAUST

10:10 - 10:20

Protein design for diagnostic devices

Prof. Stefan Arold, Prof. of Bioengineering, KAUST

10:20 - 10:30

Organic Electronic Interfaces as Sensors and Electroceuticals

Prof. Sahika Inal, Assoc. Prof. of Bioengineering, KAUST

Abstract

Abstract

In this talk, I will introduce organic mixed ionic–electronic conductors, a class of semiconducting polymers uniquely suited for bioelectronic interfaces. I will discuss how these materials enable the development of organic electrochemical transistors for sensitive and selective biochemical sensing. The biosensor technology relies on an oriented bioassembly strategy on the sensor surface, combined with the OECT’s strong output signal. I will also show the use of these materials and systems as therapeutics

for wireless stimulation of tissues.

10:30 - 10:40

AI4BioMedicine – from Vision to Reality & Translation

Prof. Jesper Tegner, Prof. of Bioscience, KAUST

Abstract

Abstract

I will discuss and show examples of how we in the AI4BioMed Team accelerate biomedical research and translation using and developing modern Artificial Intelligence. This work sets the stage for assessing challenges and opportunities in this exciting space.

10:40 - 10:50

Flexible, Wearable, and Disposable Wireless Biomedical Sensors for Remote Health Monitoring

Prof. Atif Shamim, Professor of Electrical and Computer Engineering, KAUST

Abstract

Abstract

With the advent of Health Internet of things (H-IoT), there is a new focus on wearable sensors which can wirelessly relay data for various physiological parameters and enable remote health monitoring. Due to expected large volume, there is a requirement that the cost is extremely low, to the extent that they become disposable. The flexibility and low-cost aspects can be addressed through additive manufacturing technologies such as inkjet and screen printing. This talk introduces additive manufacturing as an emerging technique to realize low cost, flexible and wearable wireless sensing systems. Many examples, ranging from a fully printed wireless ECG System to a Smart Bandage for diabetic foot ulcers will be shown. 

10:50 - 11:10

Coffee Break and Networking Session

11:10 - 11:30

Session Chair: Prof. Imed Gallouzi, KCSH Chair, KAUST

Keynote Talk from The Right Honourable The Baroness Patricia Scotland of Asthal, KC

Member of the House of Lords and

Former Secretary-General of the Commonwealth of Nations

11:30 - 12:30

Session 6: Innovation to Impact in Smart Health

Session Chair: Prof. Mo Li, Assoc. Prof. of Bioscience, KCSH Executive Committee, KAUST

11:30 - 12:00

Healthy brain ageing - challenges and opportunities

Prof. Siddharthan Chandran, Director, UK Dementia Research Institute

12:00 - 12:10

Supernumerary X Chromosomes Shape Brain Organoid Architecture and Functions in a DoseDependent Fashion

Prof. Antonio Adamo, Assoc. Prof. of Bioscience, KAUST

Abstract

Abstract

Supernumerary X Chromosomes SHAPE Brain Organoid

Architecture and Functions IN A Dose-Dependent FASHION.

Veronica Astro¹, Angels Almenar³, Rawan Alghamdi¹, Kelly

J. Cardona-Londoño¹_,Gabriel Herrera Lopez¹, Pierre Magistretti¹, Alysson Muotri³ and Antonio Adamo¹

Klinefelter syndrome (KS), also known as 47,XXY, is the most prevalent aneuploidy in males with an incidence of approximately 1:600 live male births. High-grade sex chromosome aneuploidies (HGA-SCAs), such as 48,XXXY, and 49,XXXXY are rarer conditions occurring in 1:40.000-1:80.000 males. Both KS and HGA-SCA patients exhibit a broad spectrum of neuronal impairment, including cognitive deficits, seizures, autistic traits, and motor, speech, and language delays. The severity of the clinical features in males correlates with the number of additional X complements. While KS patients typically display a milder phenotype, HGA-SCAs are associated with profound cognitive defects. Despite the prevalence of X chromosome aneuploidies, there is a critical need for cellular models to define the transcriptional and epigenetic consequences of X chromosome overdosage and its implications for neurodevelopmental disorders. In this study, we modeled the impact of X chromosome overdosage on early neurodevelopment deriving cortical organoids from 47,XXY, 48,XXXY, and 49,XXXXY iPSCs. Through a multi-layered analysis integrating morphological, functional, bulk, and single-cell transcriptomics, we demonstrated that additional X chromosomes impair neural patterning, disrupt cortical architecture, and alter the electrophysiological properties of cortical organoids in a dose-dependent manner. We leveraged the cutting-edge technology of high-density microelectrode arrays (HD-MEAs) to assess the progressive neuronal development over several months in culture through the recording of neuronal firing and the mapping of network connectivity. HGA-SCAs organoids displayed altered neuronal firing and synchronicity compared to 46,XY cortical organoids. Finally, we demonstrated significant hyperexcitability of HGA-SCA organoids and X dosage-sensitive deficits in long-term potentiation (LTP) through patch-clamp studies. Our work leverages the inaugural cohort of X aneuploid cortical organoids to model the functional consequences of X-linked gene overdosage during neurodevelopment.

12:10 - 12:20

Long-read sequencing technologies for comprehensive analysis of mutations in the nuclear and mitochondrial genomes

Prof. Mo Li, Assoc. Prof. of Bioscience, KAUST

Abstract

Abstract

My lab has developed novel targeted sequencing technologies to study genome instability in human diseases and aging. We have created several molecular biology techniques to enrich specific regions of the human genome for long-read, single-molecule sequencing, along with bioinformatics toolkits that enable ultra-sensitive, haplotype-resolved, quantitative characterization of both small and large DNA variants using the Nanopore sequencing platform. Precise delineation of genomic breakpoints remains challenging despite advancements in genetic testing. To overcome this, we developed NanoRanger™, a nanopore-based approach that rapidly and accurately resolves genomic rearrangements with minimal DNA input. Using NanoRanger™, we successfully pinpointed previously unresolved breakpoints in 13 Saudi familial cases, facilitating precise carrier status determination, founder mutation identification, and mutation frequency estimation in the Saudi population. Current mitochondrial DNA (mtDNA) sequencing methods lack sufficient sensitivity to fully resolve the complexities of mtDNA heteroplasmy. We developed individual Mitochondrial Genome sequencing (iMiGseq), which enables ultra-sensitive variant detection and complete haplotype characterization at the single-molecule level in single cells. iMiGseq identified clinically relevant mitochondrial mutations in patient-derived stem cells and uncovered previously undetectable heteroplasmic variants in healthy human oocytes, significantly advancing the understanding of mitochondrial diseases and heteroplasmy dynamics. We are now expanding the application of these long-read technologies to the precision diagnosis of cancer and the study of aging-related disorders.

12:20 - 12:30

Bioinspired, Glue-Free Skin Patches for Next-Gen Wearable Health Monitoring

Prof. Nazek El-Atab, Asst. Prof. of Electrical and Computer Engineering, KAUST

Abstract

Abstract

Bioinspired, Glue-Free Skin Patches for Next-Gen Wearable Health Monitoring

In this talk, I will present a sustainable, biocompatible patch that replaces traditional chemical adhesives with bioinspired miniaturized octopus-like suckers (AMOS), offering a comfortable and residue-free alternative for long-term skin attachment. Using a dual-3D printing approach, we engineered a stretchable and permeable biopatch with integrated microfluidic channels for enhanced breathability. The patch demonstrates strong, customizable adhesion across diverse skin conditions (dry, wet, hairy) while enabling reliable ECG, EMG and EOG monitoring during dynamic activities. This nature-inspired design marks a significant step toward environmentally friendly, high-performance wearable devices for health monitoring.

12:30 - 12:40

The Body Talks; A New Era of Wearable Intelligence

Prof. Ahmed Eltawil, Prof. of Electrical and Computer Engineering, KAUST

Abstract

Abstract

The Body Talks; A New Era of Wearable Intelligence

The human body is no longer just a subject of measurement—it is becoming the medium itself. This talk introduces Human Body Communication (HBC) as a transformative approach to connecting wearable and implantable sensors by using the body’s conductive tissue as a secure and efficient communication channel. Unlike conventional wireless methods, HBC offers ultra-low-power, interference-resilient connectivity that is ideal for continuous physiological monitoring and seamless human-machine integration. Drawing from recent advances in HBC transceiver design and system-level implementations, we explore how this technology enables a new class of body-integrated networks—paving the way for truly intelligent, context-aware wearables.

12:40 - 14:00

Lunch

Scientific posters and displays

14:00 - 15:30

Session 7: Innovation to Impact in Smart Health

Session Chair: Prof. Danesh Moradigaravand, Asst. Prof. of Bioscience, KAUST

14:00 - 14:20

Entrepreneurship: Exponential in the journey from Innovation to Impact

Dr. Nabeel Goheer, Vice President, PATH

Abstract

Abstract

Nabeel is a leader in smart technopreneurship, complex ecosystems, and societal transformation. Presently, he is the Vice President of a Seattle-based social enterprise in global health - PATH. Earlier, he worked with the United Nations and Commonwealth systems, and last served as an Assistant Secretary-General. In addition to his part time executive role, he runs a consulting business from London, and sits on the governing boards of Middlesex University, the Royal Overseas League, and the Foundation of Appropriate Technologies in Health, Switzerland. Furthermore, he is a Health Executive in Residence at the UCL Global Business School for Health; a member of the World Economic Forum’s Ai Resilient Governance and Regulation group; and a leadership resource for the UN System Staff College. Nabeel mentors technopreneurs from Harvard and MIT Universities and Ignyte Dubai. He is an engineer, holds an M.Phil. in Technology Policy, and a Ph.D. from the Judge Business School of University of Cambridge, UK.

14:20 - 14:30

Chugai’s Technology-Driven Approach to Drug Discovery

Dr. Hideaki Shimada, CEO and Research Head, Chugai Pharmabody Research Pte. Ltd.

Abstract

Abstract

Chugai’s Technology-Driven Approach to Drug Discovery

Chugai Pharmaceutical, Japan's leading pharmaceutical company, implements a unique "technology-driven drug discovery" strategy based on proprietary modality technologies including Recycling Antibody®, Sweeping Antibody®, mid-size molecules, and small molecules. Unlike conventional pharmaceutical approaches focused on specific therapeutic areas, Chugai applies its technologies across disease areas to address unmet medical needs. This approach has yielded breakthrough drugs such as ACTEMRA®, ALECENSA®, and HEMLIBRA®. The Chugai research subsidiary in Singapore, Chugai Pharmabody Research (CPR), focuses on early-stage drug discovery and actively collaborates with the local ecosystem, as exemplified by the development of AID351 for dengue fever in collaboration with A*STAR. CPR has utilized its antibody engineering and cyclic peptide platforms to invent drugs with global impact, including PIASKY®. Through continuous investment in technology development, Chugai aims to expand the "druggable space" and create first-in-class and best-in-class medicines that contribute to global healthcare innovation.

14:30 - 14:40

Arabian Incense Burning as an Indoor Source of Fine Particles: Abundance and Oxidative Potential

Prof. Chak Chan, Prof. of Chemical Engineering, Dean of PSE, KAUST

Abstract

Abstract

Arabian Incense Burning as an Indoor Source of Fine Particles: Abundance and Oxidative Potential

Liyuan Zhou and Chak K. Chan

Division of Physical Science and Engineering

KAUST

Arabian Incense (Bakhoor) burning, a widespread indoor traditional practice across the Middle East, involves the combustion of aromatic woodchips infused with scented oils and resins. Despite its prevalence, the air quality and health implications of this activity remain underexamined. This study provides a comprehensive analysis of fine and ultrafine particle emissions from three commercially available Bakhoor products, including particle abundance, chemical composition, oxidative potential, and cellular oxidative stress. Emission rates ranged from 700 to 2500 μg min⁻¹ and (6–7) × 10¹¹ particles min⁻¹ per gram burned, placing Bakhoor within the upper range of known indoor emission sources. These emissions may be influenced by the quantity and composition of scented oils present in the products. High-resolution mass spectrometry showed that particle-phase compounds were dominated by CHO and CHON species, with oxygen-to-carbon (O:C) ratios predominantly below 0.6 and aromaticity indices (AImod) generally under 0.5, indicating moderate oxidation and relatively low aromatic content. DTT-based redox activity of Bakhoor particles averaged ~30 pmol min⁻¹ μg⁻¹, which is lower than that of cigarette smoke (~50 pmol min⁻¹ μg⁻¹), included here as a benchmark for comparison, and falls within the range reported for other biomass emissions. In contrast, Bakhoor particles induced higher levels of intracellular reactive oxygen and nitrogen species (ROS/RNS) in alveolar macrophages compared to cigarette smoke. The ROS/RNS responses persisted even after simulated indoor ozone aging for 6 days. Overall, these findings indicate that Bakhoor burning is a notable source of indoor fine particle pollution, with potential implications for human exposure and respiratory health.

14:40 - 14:50

From Radar Waves to Wellness: A Novel Approach to Dehydration Sensing

Dr. Sajid Ahmed, Research Scientist with Prof. Mohamed-Slim Alouini (Assoc. VP, Research), KAUST

Abstract

Abstract

In this work, we introduce an innovative, noninvasive approach for detecting and classifying dehydration using advanced radar technology. By employing frequency modulated continuous wave radar systems operating at 10 GHz and 77 GHz, we are able to monitor individuals safely and effectively without any physical contact. A key part of our methodology is the precise processing of radar signals to isolate the target of interest, ensuring that only accurate and meaningful information is used for further analysis. To capture the subtle and complex patterns associated with dehydration, we implemented a sophisticated feature extraction technique known as wavelet scattering transform. This method enables machine learning models to detect nonlinear and otherwise hidden indicators of dehydration with greater accuracy. Our approach has demonstrated strong potential for real-time, non-contact monitoring of dehydration, making it especially promising for applications in remote healthcare settings, where accessibility, safety, and continuous monitoring are critical. Through this work, we aim to contribute to the development of practical, scalable solutions for proactive health monitoring.

14:50 - 15:00

Unlocking Microbial Diversity for Smart Health: From Vaults & Mini-Guts to One Health Innovation

Prof. Alexandre Rosado, Prof. of Bioscience, KAUST

Abstract

Abstract

At KAUST, we are unlocking the hidden power of microbial diversity to rethink how we care for human and environmental health. Through the Microbial Vault, we preserve and harness microbiomes from diverse ecosystems. In this presentation, I will highlight our work using mini-gut organoids to model microbe-host interactions and microbiome and metabolome studies investigating gut signatures associated with liver disease progression in the Saudi population. I will also present our efforts to discover microbes capable of degrading microplastics and producing natural sunscreens and to develop phage- and endolysin-based therapies targeting antibiotic-resistant pathogens. By integrating environmental and clinical microbiomes, our research demonstrates how microbial innovation can drive sustainable, next-generation health solutions and contribute to a resilient One Health future for people and the planet.

15:00 - 15:10

Genomic Insights into Multidrug-Resistant Hypervirulent Klebsiella pneumoniae

Prof. Danesh Moradigaravand, Asst. Prof. of Bioscience, KAUST

Abstract

Abstract

Genomic Insights into Multidrug-Resistant Hypervirulent Klebsiella pneumoniae

Klebsiella pneumoniae is a Gram-negative bacterium responsible for a wide range of community- and hospital-acquired infections. The emergence of clonal hypervirulent strains resistant to last-resort antimicrobials has become a major global health concern. In this talk, I will present recent genomic insights into the population structure and dynamics of K. pneumoniae isolates recovered from hospitals in the Kingdom of Saudi Arabia. I will discuss the emergence of multidrug-resistant hypervirulent (MDR-Hv) clones and highlight the critical role of plasmid dynamics in driving the evolution of these high-risk lineages.

15:10 - 15:20

From Crisis to Preparedness: Advancing Health Security with a Rapid-Response Vaccine Platform

Prof. Magnus Rueping, Prof. of Chemical Science, KAUST

15:20 - 15:30

Novel Therapeutics to Prevent Disease Induced Muscle Loss

Prof. Imed Gallouzi, Prof. of Bioscience, KCSH Chair, KAUST

15:30 - 15:40

Event Closing Remarks

Prof. Imed Gallouzi, KCSH Chair, KAUST

SPEAKERS

HRH Prince Sultan bin Salman bin Abdulaziz Al Saud

His Royal Highness Prince Sultan bin Salman bin Abdulaziz Al Saud

Special Advisor to the Custodian of the Two Holy Mosques, Chairman of the Board of Trustees of the Non-profit King Salman Foundation, and Chairman of the Board of Trustees of the King Salman Center for Disability Research (KSCDR).

His Royal Highness Prince Sultan bin Salman bin Abdulaziz Al Saud is a prominent figure in Saudi Arabia, He obtained a Master's degree in Social and Political Sciences from the Maxwell School of Citizenship and Public Affairs at Syracuse University, USA, in 1999.

His professional career began as a military pilot in the Royal Saudi Air Force from 1405H to 1416H. He holds a civil aviation license from the Federal Aviation Administration (FAA) in the USA. He also served as an astronaut, participating in the Space Shuttle Discovery mission STS-51G in 1985.

Prince Sultan has held numerous official positions, including:

• Chairman of the Saudi Space Commission (2018-2021)

• Special Advisor to the Custodian of the Two Holy Mosques with the rank of Minister since 2021

• Chairman of the Board of Trustees of the King Salman Nonprofit Foundation since 2021

• Chairman of the Board of the Saudi Commission for Tourism and National Heritage (2008-2018)

He has also founded and chaired various initiatives and committees such as:

• King Salman bin Abdulaziz Initiative for the Care of National Heritage (2011-2018)

• Prince Sultan bin Salman Chair for Mosque Architecture at Imam Abdulrahman bin Faisal University (2017)

• Salman bin Abdulaziz Program for the Care of Cultural Heritage

Prince Sultan has been honored with numerous awards and medals from various countries and international organizations in recognition of his achievements and contributions in the fields of space, tourism, heritage, and disability. These include the King Abdulaziz Sash of the First Class, honorary doctorates from several universities, and global awards in tourism and heritage.

Prof. Imed Gallouzi

KCSH Chair, KAUST

Professor Sir Edward Byrne, AC

President of KAUST

Ibn Sina Distinguished Prof. Pierre Magistretti

VP for Research, KAUST

Dr. Mehmood Khan

CEO, Hevolution Foundation

Dr. Mehmood Khan

Chief Executive Officer of Hevolution Foundation.

Dr. Mehmood Khan’s distinguished career has included several senior corporate roles, including Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, and President of Global R&D Center at Takeda Pharmaceuticals.

Before moving into the private sector Dr. Khan was a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also led programs in diabetes, endocrinology, metabolism, and nutrition in Minneapolis.

Dr. Khan is a member of the Board of Directors of Reckitt Benckiser and of the Saudi Research, Development, and Innovation Authority (RDIA), Executive Chairman of Life Biosciences, a member of the Saudi National Biotechnology Strategy Steering Committee, and past Chairman of the Visiting Committee on Advanced Technology of the United States’ National Institute of Standards and Technology (NIST).

Dr. Khan earned his medical degree from the University of Liverpool School of Medicine, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians in London, a Fellow of the American College of Endocrinology, and an Elected Fellow in the Department of Pharmacology at University of Oxford.

Mr. Sami AlSager

Vice President for Operations, Saudi Food & Drug Authority (SFDA)

Mr. Sami AlSager

Sami Alsager is holding a master degree in Health and Hospital Administration from King Saud University in 2007. He got his Bachelor degree in Pharmaceutical Sciences from the college of Pharmacy at King Saud University in 2002.

During his career in SFDA, he was appointed as a Director for couple of departments.

• Executive Director for Cosmetic Products Safety. During that period, he implemented the listing plan of cosmetic products in the cosmetic products listing system (eCosma) which acts as a database for all cosmetic products marketed in the country - October 2014.

• Vice President for Drug Affairs to be in charge for all regulatory activities related pharmaceutical and cosmetic products in SFDA -April 2017

• Vice President for Operation Sector to take over all SFDA functions related to licensing and inspection activities in addition to customer services activities - February 2018.

He was a member of the team who participated effectively in developing the regulatory infrastructure of SFDA in terms of setting the regulation and guidelines as well as the processes in the Drug Sector at the SFDA. He participated in many projects and committees such as:

• Developing the first draft of the Regulatory Framework for Drug Approvals.

• Reviewing the pricing guideline of pharmaceutical products.

• Developing the requirements for electronic systems such as:

Saudi Drug Registration System (SDR)
Establishment Licensing System
Products Classification System

• Developing Products Classification Guidelines

• Developing the Executive Regulation of Cosmetic Law.

• Developing Gulf Veterinary products law and its Executive Regulation.

He has an article published in Pharmaceutical Medicine Journal, April 2015 about The Saudi Food & Drug Authority: Shaping the Regulatory Environment in the Gulf Region.

Prof. Robert Hoehndorf

Assoc. Prof. of Computer Science, KAUST

Dr. Abdullah bin Zarah

CEO of Prince Sultan bin Abdulaziz Humanitarian City (SBAHC)

Dr. Abdullah bin Zarah

CEO of Prince Sultan bin Abdulaziz Humanitarian City (SBAHC)

With over 27 years of accomplished service across private, not-for-profit, and government sectors, primarily within healthcare, Abdullah has a strong track record of initiating and contributing to the development and implementation of strategic plans, organizational turnarounds, and transformations.

His academic credentials include a Master's in Public Health from Tsukuba University (Japan), Six Sigma Black Belt certification in Management and Strategic Performance Improvement, and recognition as an INSEAD Leadership Fellow. He has also completed the Executive Leadership Program at Harvard University (USA) and is currently pursuing a Doctorate in Strategic Planning and Organizational Psychology at Northampton University (London, UK).

Since joining Sultan Bin Abdulaziz Humanitarian City (SBAHC) in 2005, a world-class organization, Abdullah has served as its Chief Executive Officer and actively participates in numerous local and international boards and specialized committees, including the Sultan bin Abdulaziz Foundation, IMS University, and Planetree International.

Eng. Nizar Al Hariri

Senior Advisor to the Minister of Industry and Mineral Resources

Eng. Nizar Al Hariri,

Senior Advisor to the Minister of Industry and Mineral Resources

Over 30 Years of Experience in Industrial and Business Development sectors, including 20 years in the pharmaceutical manufacturing industry.

Served as the CEO of the first factory built in Saudi Arabia and the Middle East to produce Active Pharmaceutical Ingredients (APIs).

Held numerous of managerial positions, most recently as the CEO of the National Center for Industrial Development.

Currently serves as an advisor to the Minister of Industry and Mineral Resources for the development of the pharmaceutical, Biotechnology, Medical devices and equipment sectors.

Dr. Abdullah M. Asiri,

Deputy Minister for Population Health, Ministry of Health (MoH) KSA

Dr. Mahmoud AlYamany,

Head of NEOM Health and Wellbeing, NEOM

Dr. Mahmoud AlYamany

Dr. Mahmoud Al Yamany is a distinguished healthcare leader with extensive experience in strategy, governance, and operational excellence. He currently serves as the Sector Head for Health and Wellbeing at NEOM and holds multiple board positions, including Co-Chairman of the Western Healthcare Clusters. Formerly CEO of Riyadh Second Health Cluster and King Fahad Medical City, he is a board certified neurosurgeon in both the U.S. and Canada, with subspecialty training from the University of Toronto. Dr. Al Yamany earned his Master’s in Executive Health Administration from Washington University and serves as an adjunct professor at McGill University. He is known for his innovative leadership and commitment to advancing healthcare transformation in Saudi Arabia.

Dr. Petros Kotsidis

Chief Digital Officer, King Faisal Specialist Hospital &Research Centre (KFSH&RC)

Dr. Petros Kotsidis is a distinguished Chief Digital Officer (CDO) with extensive experience in driving digital transformation and data innovation within the healthcare and life sciences sectors. Renowned for his expertise in leveraging digital technologies to create value from data, Dr. Kotsidis has successfully led a variety of high-impact projects in healthcare, including AI/ML-driven predictive models, advanced digital analytics platforms, and the development of cutting-edge digital products that optimise clinical and operational outcomes.

Mr. Melvin D’Souza

Corporate Vice President

& General Manager, Novo Nordisk Saudi Arabia

Melvin joined Novo Nordisk in 1995 and has been instrumental in establishing Novo Nordisk as a trusted leader in diabetes care, obesity, hemophilia, and growth hormone disorder in various countries across Asia and Middle East.

In his distinguished career with Novo Nordisk spanning almost three decades, Melvin has held local & global leadership positions in Sales, Direct to Consumer, Marketing, and general management. Before taking over as the General Manager for Novo Nordisk India, he successfully established the Novo Nordisk business in Gulf and UAE. In 2019, he became Corporate Vice President and General Manager for Saudi Arabia affiliate.

Melvin has been leading various affiliates of Novo Nordisk since 2006. During his time in India, the business area grew more than 5 times and became one of the fastest growing pharmaceutical MNCs with a strong vision for the future. This transformation is defined by a unique patient centric business approach towards value creation and providing innovation for the benefit of key stakeholders. In 2013, Melvin was named International Operations Manager of the Year. Under his able leadership, Novo Nordisk India with its unique learning and collaborative culture has also been recognized as one of the top employers in the MNC pharmaceutical space and has received numerous accolades for its commitment towards society and environmental stewardship.

As Corporate Vice President & General Manager of Novo Nordisk Saudi Arabia, Melvin's dedication, energy, and strategic thinking have led to significant achievements. He has shifted operations from distributor to Trading Entity in short span of 1.5 years, significantly impacting patients to access with localized products. His leadership has driven consistent double-digit growth, resulting in the organization being recognized as ‘best place to work’ in Saudi Arabia since 2019 and 1st ‘best place to work for women’ in the kingdom.

Melvin was a graduate in Pharmacy from JSS College, a Postgraduate in Pharmaceutical Management from COPS, Manipal and a Postgraduate in Business Management from ALBA, Greece.

Dr. Essam A. Tawfik

General Manager of Advanced Diagnostics & Therapeutics Institute,

KACST

Dr Essam Tawfik

Dr Essam Tawfik is the General Manager of Advanced Diagnostics and Therapeutics Institute in the Health sector at King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia. He was a consultant at DVS Pharmaceuticals as the GCC Medical Lead to introduce a new vaccine in the Kingdom and the GCC, and a former assistant manager of the monitoring office for scientific affairs in the Saudi Arabia National Committee of Bioethics at KACST.

Dr Tawfik is one of the few researchers to work in tissue engineering in Saudi Arabia, using electrospinning technology to manufacture drug-loaded nanofibrous scaffolds. Essam has published 3 patents, more than 50 articles and 3 book chapters since his PhD award in 2019. He holds a PhD in Pharmaceutics from University College London - School of Pharmacy, and has more than a decade of experience in Pharmaceutics and is passionate about different drug delivery technologies.

Prof. Arnab Pain,

Prof. of Bioscience, KAUST

Prof. Xin Gao

KCSH co-Chair, KAUST

Prof. Samir Hamdan

Prof. of Bioscience, Associate VP and COO for Research, KAUST

Prof. Bruno Reversade

Prof. of Bioscience, KAUST

Prof. Dana Al-Sulaiman

Assistant Prof. of Material Science and Engineering, KAUST

Prof. Khaled Salama

Prof. of Electrical and Computer Engineering, KAUST

Prof. Magnus Rueping

Prof. of Chemical Science, KAUST

Prof. Ahmed Eltawil,

Prof. of Electrical and Computer Engineering, Associate Dean for Research, CEMSE, KAUST

Prof. Leena Ibrahim,

Asst. Prof. of Bioscience, KAUST

Dr. Paul O’Callaghan,

Family and Child Support Center (FCSC), KAUST

Dr. Paul O’Callaghan

Manager of the Family and Child Support Center

Dr Paul obtained a teaching diploma from University College Dublin and his doctorate in Education, Child, and Adolescent Psychology from Queen’s University, UK in 2012. After qualifying, he worked as an educational psychologist for four years in the largest local Education Authority in the UK before moving to work as the School Psychologist at The KAUST School. His research interests include learning needs and mental health, and he has authored and co-authored papers in the journals of Child Psychology and Psychiatry, The Lancet Global Health, and Dyslexia. He has advanced training in administering developmental, psycho-educational, and autism assessments. Paul is a trained PACT (Autism) and Orton-Gillingham (Structured Literacy) therapist. He manages the Family and Child Support Center – which offers intervention support to around 200 children every year. He lives in King Abdullah University of Science and Technology with his wife and three children

Prof. Jasmeen Merzaban,

Assoc. Prof. of Bioscience, KCSH Executive Committee, KAUST

Prof. Matthias Hentze

Director, European Molecular Biology Laboratory (EMBL)

Matthias Hentze

Matthias Hentze is currently the Director of the European Molecular Biology Laboratory (EMBL). Following medical studies in Germany and the UK, and his qualification as a medical doctor, he obtained his postdoctoral training at the NIH (USA) in the late 1980s, when he and his colleagues discovered “iron-responsive elements” as the first mammalian regulatory elements in mature mRNAs. After two decades of elucidating mechanisms of RNA regulation by RNA-binding proteins, recent work by the Hentze group has uncovered hundreds of new RNA-binding proteins, including many metabolic enzymes. Supported by an ERC Advanced Grant and other funds, their current work uncovers new roles of RNA in riboregulation and elucidates connections between metabolism and gene regulation. Prof. Hentze is a co-founder of the MMPU, a joint interdisciplinary and translational research unit of the Medical Faculty of Heidelberg University and the EMBL, which bridges between medicine and molecular biology. Matthias Hentze’s research contributions have been recognized in numerous ways including Germany’s most prestigious scientific award, the Gottfried Wilhelm Leibniz Prize in 2000, the 2007 Lautenschläger Research Prize of Heidelberg University, and the 2015 Feodor Lynen Medal of the German Society for Biochemistry and Molecular Biology. He is also the 2020 recipient of the Lifetime Achievement Award of the RNA Society and the 2023 recipient of the Centenary Award of the Biochemical Society. He received an honorary doctorate by the Australian National University in Canberra, and is an elected member of the European Molecular Biology Organisation (EMBO), the German Academy of Sciences Leopoldina, and the Academia Europaea. In 2016, he became the first German scientist elected as a Corresponding Member of the Australian Academy of Science, and in 2018 he was elected into the American Academy of Arts and Sciences as an International Honorary Member. He was a co-founder of Anadys Pharmaceuticals (San Diego) and serves on numerous international scientific advisory and editorial boards. In 2020, he initiated the Environmental Research Initiative and Fund at EMBL. Prof. Hentze is the recipient of the Otto Warburg Medal 2025 of the Society for Biochemistry and Molecular Biology.

Dr. Khalid Al-Rubeaan

Director, Research & Scientific Center, Prince Sultan Bin Abdulaziz

Humanitarian City (SBAHC)

Dr. Khalid Al-Rubeaan,

Director, Research & Scientific Center, Prince Sultan Bin Abdulaziz Humanitarian City (SBAHC)

A Full Professor of Endocrinology and Internal Medicine, working currently as Director of Research and Scientific Center at Sultan Bin Abdulaziz Humanitarian City. Former Head of University of Diabetes Center and the Strategic Center for Diabetes Research. A Part-time WHO consultant for Regional Office for the Eastern Mediterranean region (EMRO) and the chairman of board of trustee and founder of Diabetes Science International Foundation, Basal, Switzerland. He is Editor-in-Chief for International Journal of Diabetes Mellitus and Al-Sukhari Magazines (مجلة السكري).

Prof. Al-Rubeaan published scientific books in both English and Arabic language and chapters in medicine, genetic, medical Bioinformatics and diabetes different fields. He published more than 150 scientific papers and was recognized to be one of the top 2% Career-long Citation Scientist in the world Ranked List by Stanford University in 2022. He was also awarded the King Saud University Award for Scientific Excellence in 2018 and the Riyadh Book Fair for the best medical books in 2017. He was also awarded the King Abdulaziz City for Science & Technology (KACST) BADIR award 2013 and received Novo Nordisk Research Merit Award in Diabetes in 2002. Professor Al-Rubeaan was given the Arabian Award for Diabetes Education 2001.

Prof. Bernard Ghanem,

Chair of Center of Excellence for Generative AI, KAUST

Prof. Husam AlShareef,

Chair of the CoE for Renewable Energy and Storage Technologies, KAUST

Prof. Salim Al-Babili

Prof. of Plant Science, Associate Dean, BESE, KAUST

Prof. Stefan Arold,

Prof. of Bioengineering, KAUST

Prof. Sahika Inal,

Assoc. Prof. of Bioengineering, KAUST

Prof. Atif Shamim

Prof. of Electrical and Computer Engineering, KAUST

Prof. Jesper Tegner

Prof. of Bioscience, KAUST

Prof. Siddharthan Chandran,

Director, UK Dementia Research Institute

Siddharthan Chandran

Director of the UK MRC Dementia Research Institute

Siddharthan Chandran is Director of the UK MRC Dementia Research Institute. He graduated from Southampton Medical School, trained in neurology at Queens Square, UCL and Cambridge where he also undertook a PhD in developmental neurobiology. He holds the MacDonald Chair of Neurology, at the University of Edinburgh, is Professor of Neurology at University College London, and Visiting Faculty at the Centre for Brain Research, Indian Institute of Science, India. He is best known for his work in motor neuron disease (MND) and multiple sclerosis (MS). His work encompasses the use of human induced pluripotent stem cells to identify cellular phenotypes of neurodegenerative diseases (NDDs) as well as pioneering innovation in multi-arm, multi-stage platform trials for NDDs. He is a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences.

Prof. Mo Li,

Assoc. Prof. of Bioscience, KAUST

Dr. Nabeel Goheer

Vice President, PATH

Dr. Nabeel Goheer

Nabeel is a seasoned leader in emerging technologies, complex ecosystems, and societal transformation. Presently, he is the Vice President of PATH - a Seattle-based enterprise in global health. Earlier, he was a multilateral diplomat with the United Nations and Commonwealth systems, and last served as an Assistant Secretary-General. In addition to his executive role, he sits on the governing boards of Middlesex University, the Royal Overseas League, and the Foundation of Appropriate Technologies in Health, Switzerland. Furthermore, he is a Health Executive in Residence at the UCL Global Business School for Health; a member of the World Economic Forum’s Ai Resilient Governance and Regulation group; and a leadership resource for the UN System Staff College in Italy. Nabeel also mentors technopreneurs from Harvard and MIT Universities, Ignyte Dubai, as well as Commonwealth countries. He is an engineer, holds M.Phil. in Technology Policy, and Ph.D. from the Judge Business School of University of Cambridge.

Prof. Antonio Adamo,

Assoc. Prof. of Bioscience, KAUST

Dr. Hideaki Shimada

CEO and Research Head, Chugai Pharmabody Research Pte. Ltd.

Dr. Hideaki Shimada, CEO and Research Head, Chugai Pharmabody Research Pte. Ltd.

Dr. Shimada joined Chugai Group in 2010 and has more than 20 years of experience in the pharmaceutical industry. He led several antibody and small molecule projects in the areas of immunology, fibrosis, cancer, or metabolic diseases. Prior to joining Chugai Group, he held various positions in Pfizer.

Prof. Nazek El-Atab

Arsst. Prof. of Electrical and Computer Engineering, KAUST

Prof. Alexandre Rosado,

Prof. of Bioscience, KAUST

Prof. Danesh Moradigaravand

Asst. Prof. of Bioscience, KAUST

Prof. Chak Chan,

Prof. of Chemical Engineering, Dean of PSE, KAUST

Dr. Sajid Ahmed

Research Scientist, KAUST

KAUST Centers of Excellence

KAUST Launches Four Pioneering Centers of Excellence to Address Key National and International Priorities

LEARN MORE

Generative AI

Renewable Energy and Storage Technologies

Smart Health

Sustainable Food Security

KAUST CORE LABS

KAUST hosts a wide range of sophisticated instruments and world-class facilities that students can access, including the Prototyping and Product Development Core Lab, and laboratories involving robotics and embedded systems, sensors, intelligent autonomous systems and biotechnology. Specific labs will be identified based on the curriculum and individual projects.

LEARN MORE

KAUST IMPACT

KAUST Impact Summer 2024, the latest edition

of the magazine.

DOWNLOAD

KAUST IMPACT

A NEW ERA FOR KAUST

Our unrelenting commitment to research, innovation and talent has seen KAUST establish itself as one of the leading research universities in the world, ranking #1 for citations per faculty globally, with a reputation for impact-driven research that contributes to the betterment of the world. This new era of KAUST builds on our many successes, achievements and strong foundations, and our new strategy represents an evolution that brings us closer to the interests of the Kingdom.

LEARN MORE

King Abdullah University of Science and Technology (KAUST)

4700 King Abdullah University of Science and Technology

Thuwal 23955-6900

Kingdom of Saudi Arabia